Myxomatous mitral valve disease is the most common heart diseases in dogs with increased prevalence in small breed and older dogs. This condition has remained a challenge to manage, and pre-clinical stages are commonly overlooked. The use of nucleotide biomarkers holds the potential to transform veterinary care of cardiac disease by facilitating early intervention and lead to better health outcomes for pets.
A recent study, published by pioneering veterinary diagnostics company MI:RNA, has revealed that microRNAs can be effectively used in diagnostics not just to identify the disease but also to give an indication of the stage, differentiating between pre-clinical and clinical stages.
Dr Robert Coultous, CSO and co-founder at MI:RNA, said: “Early detection is essential for significantly improving the longevity and quality of life of dogs, especially those at risk for this challenging disease. Our research marks a significant advance in personalised veterinary care and diagnostic technique. By identifying this disease before symptoms arise, we’re empowering veterinarians with a valuable tool to intervene early, helping to potentially slow the progression of heart disease and prevent lasting damage.”
The comprehensive study, published in Frontiers in Veterinary Science, analysed samples from 123 dogs and was conducted in collaboration with the University of Liverpool Small Animal Teaching Hospital.
The results shown in the peer reviewed article revealed a convincing ability to distinguish between healthy dogs and those with MVD as well as the potential to differentiate between dogs with preclinical and clinical MVD. These findings, conclude the authors, show that microRNA diagnostic technology has promising potential, not only in the field of veterinary cardiology but also for current and future applications across the broader veterinary sphere.
The pioneering approach from MI:RNA’s scientists harnesses the latest advancements of molecular diagnostics with advanced predictive modelling to offer a reliable and efficient screening method, and underlines their commitment to enhancing animal health through scientific innovation and collaboration.
Dr Robert Coultous added: “Our collaborative study strengthens our commitment to enriching and extending the lives of pets, guided by our innovative diagnostic platform and deep dedication to their well-being.”
